Skip to main content

Table 7 Incidence and incidence rates of primary, secondary, and tertiary end points

From: Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events

  Linagliptin (n = 5847) Total comparators (n = 3612)
  Incidence n (%) Incidence rate (per 1000 years) Incidence n (%) Incidence rate (per 1000 years)
Primary end points     
CV death, stroke, MI, or UAP with hospitalization 60 (1.0) 13.4 62 (1.7) 18.9
Secondary end points     
CV death, stroke, or MI 42 (0.7) 9.3 46 (1.3) 14.0
All major CV events 96 (1.6) 21.5 95 (2.6) 29.1
FDA-custom MACE 39 (0.7) 8.7 45 (1.3) 13.7
Tertiary end points     
CV death 11 (0.2) 2.4 8 (0.2) 2.4
Non-fatal MI 23 (0.4) 5.1 20 (0.6) 6.1
Non-fatal stroke 9 (0.2) 2.0 19 (0.5) 5.8
TIA 1 (0.02) 0.2 8 (0.2) 2.4
UAP with hospitalization 22 (0.4) 4.9 16 (0.4) 4.8
Hospitalization for CHF* 12 (0.6) 8.8 9 (0.7) 8.4
Total mortality 18 (0.3) 4.0 16 (0.4) 4.8
  1. CHF, congestive heart failure; CV, cardiovascular; FDA, Food and Drug Administration; MACE, major adverse CV events; MI, myocardial infarction; TIA, transient ischemic attack; UAP, unstable angina pectoris.
  2. *Includes data only from trials with prospective independent adjudication of hospitalization for CHF (n = 3314).